Tag: real-world evidence
-
Upadacitinib Maintains 1-Year Benefit for Pediatric IBD: New Findings from a Single-Center Study
Overview New findings presented from a single-center retrospective study suggest that upadacitinib (Rinvoq), a JAK1 inhibitor, provides durable clinical benefit over a 12-month period for children and adolescents with inflammatory bowel disease (IBD). The study, conducted in a pediatric population with Crohn’s disease (CD) or ulcerative colitis (UC), underscores the potential of targeted therapy to…
-
MYndspan Explores How Sleep Quality Shapes Brain Function in Real Time With MEG
New Real-Time Insights into Sleep and the Brain Sleep is essential for cognitive performance and daily functioning, but until now, linking everyday sleep quality to immediate changes in brain activity was difficult to observe outside specialized labs. MYndspan is changing that by leveraging clinical-grade magnetoencephalography (MEG) to monitor brain function in real time. The company’s…
-
ESMO Guidelines Webinar: Real World Cases — Cervical Cancer 2026 Highlights
Overview of the ESMO Guidelines: Real World Cases – Cervical Cancer 2026 The Oncology community is set for a focused virtual session on June 24, 2026, as the ESMO Guidelines: Real World Cases – Cervical Cancer 2026 webinar takes center stage. Chaired by the renowned gynecologic oncologist Ana Oaknin, this virtual scientific session is designed…
-
Ireland’s Bleeding Disorders Research: Redrawing International Practices
Overview: What the research is about My work centers on inherited bleeding disorders, a group that includes well-known conditions like haemophilia and less familiar ones such as von Willebrand disease. These disorders share a common challenge: a tendency to bleed more easily due to genetic factors that affect blood clotting. While the specifics of each…
-
Monoclonal Antibody Protects Children from RSV: Real-World Insights
RSV’s Burden on Young Lungs Respiratory syncytial virus (RSV) remains a leading cause of hospitalization for infants and young children worldwide. While most kids recover with supportive care, a subset experiences severe disease that can require intensive care. In this context, scientists have been pursuing preventive strategies beyond vaccines, including long-acting monoclonal antibodies that offer…
-
Remdesivir During COVID-19 Hospitalization Linked to Lower Long-Term Mortality in Survivors: Real-World Evidence
Overview: Remdesivir and long-term outcomes after COVID-19 hospitalization Remdesivir (RDV) has been evaluated for short-term benefits in both hospitalized and non-hospitalized patients with COVID-19. However, its impact on long-term outcomes, particularly for patients who survive the initial hospitalization, has been less clear. A real-world study across three health systems in Colorado and Utah examined whether…
-
Remdesivir Linked to Lower Long-Term Mortality After COVID-19 Hospitalization: Real-World Evidence
Overview New real-world data from three health systems in Colorado and Utah suggest that receiving remdesivir (RDV) during a COVID-19–related hospitalization is associated with lower all-cause mortality after discharge. The study analyzed patients who survived their initial hospitalization and followed them for up to 29 months to assess long-term outcomes, including mortality, readmission to hospital,…
-
Remdesivir Linked to Lower Long-Term Mortality After COVID-19 Hospitalization
What the study investigated Researchers examined whether remdesivir (RDV), given during a COVID-19 hospitalization, is associated with reduced mortality after discharge among survivors. Using real-world data from three large health systems in Colorado and Utah, the study followed patients who survived their index hospitalization for 6 to 29 months to assess long-term outcomes beyond the…